Screener
Avalo Therapeutics AVTX Stock-Based Comp
Stock-Based Comp at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Avalo Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Avalo Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:03 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001534120-26-000049
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Net loss | $(55,988) | $(33,914) |
| Adjustments to reconcile net cash used in operating activities: | ||
| Depreciation and amortization | 34 | 269 |
| Stock-based compensation | 8,880 | 5,959 |
| Accretion of available-for-sale investments, net | (524) | (146) |
| Change in fair value of contingent consideration | 6,574 | — |
| Contingent consideration paid pursuant to AlmataBio Transaction | (4,813) | — |
| Change in fair value of derivative liability | 530 | 2,150 |
Item 1. Financial Statements.
FAQ
- What is Avalo Therapeutics's stock-based comp?
- Avalo Therapeutics (AVTX) reported stock-based comp of $5.31M in Q2 2026.
- How has Avalo Therapeutics's stock-based comp changed year-over-year?
- Avalo Therapeutics's stock-based comp increased by 95.2% year-over-year, from $2.72M to $5.31M.
- What is the long-term trend for Avalo Therapeutics's stock-based comp?
- Over 4 years (2021 to 2025), Avalo Therapeutics's stock-based comp has grown at a 13.6% compound annual growth rate (CAGR), from $8.17M to $13.62M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about Avalo Therapeutics's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude